Boehringer Ingelheim Acquires Nerio Therapeutics
August 6, 2024
Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.
- Buyers
- Boehringer Ingelheim
- Targets
- Nerio Therapeutics, Inc.
- Sellers
- Avalon Ventures, Bregua Corporation, Correlation Ventures, Alexandria Venture Investments, Viva BioInnovator (VBI)
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Valerio Therapeutics Acquires Etherna Immunotherapies
August 17, 2026
Biotechnology
Valerio Therapeutics acquired 100% of Etherna Immunotherapies at an enterprise value of €30 million, funded through cash consideration and contributions of Etherna shares. The acquisition combines Valerio’s cell-targeting technology with Etherna’s RNA chemistry, lipid nanoparticle delivery and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.
-
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
June 18, 2026
Healthcare Services
Biogen entered into a definitive agreement to acquire RayThera, a private immunology-focused biotechnology company, for total consideration of up to $1 billion driven by an upfront payment plus clinical and regulatory milestone payments. The deal is expected to close in the third quarter of 2026, with Biogen taking over development, manufacturing, and global commercialization of RayThera’s small-molecule anti-inflammatory assets.
-
Innova Therapeutics Acquires Enci Therapeutics
November 27, 2025
Biotechnology
Innova Therapeutics has completed the acquisition of Enci Therapeutics, adding Enci’s lead oncology program, IVT-8086, a first-in-class humanized monoclonal antibody targeting SFRP2, to its development pipeline. Financial terms were not disclosed; Innova said the program and associated IP (patents through at least 2042) will support development across multiple solid and hematologic cancers and a companion diagnostic is in development.
-
Eilean Therapeutics Acquires Ness Therapeutics
March 4, 2024
Biotechnology
Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.
-
Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences
June 14, 2022
Biotechnology
Boehringer Ingelheim has signed an option agreement to acquire Trutino Biosciences, a San Diego-based pre-clinical biotech company focused on next-generation cytokine therapies. The deal is structured as an option with an option fee, issuance of a convertible note, and a fixed purchase price triggered upon achievement of specified program milestones.
-
BioVie Acquires Biopharma Assets of NeurMedix
June 11, 2021
Pharmaceuticals
BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.